https://www.selleckchem.com/products/c381.html
Molecular docking analysis of EGFR binding site with parthenolide show that the anti-cancer effect of parthenolide against NSCLC is mediated by a strong binding to EGFR. Network pharmacology analysis show parthenolide suppresses NSCLC via inhibition of EGFR expression. In addition, parthenolide inhibits the growth of H1975 xenografts in nude mice, which is associated with the inhibition of the EGFR signaling pathway. Taken together, these results demonstrate effective inhibition of parthenolide in NSCLC cell growth by targeting EGFR throug
Curtir
Comentario
Compartilhar
